Roivant Sciences' experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's.
Outcomes were similar with each intervention overall, but the medication appeared to produce better outcomes in women with a cervical length of 25 mm or less.